Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;8(11):1126-1134.
doi: 10.1002/sctm.19-0073. Epub 2019 Jul 7.

Mesenchymal Stromal Cells Anno 2019: Dawn of the Therapeutic Era? Concise Review

Martin J Hoogduijn  1 , Eleuterio Lombardo  2
Affiliations
Review

Mesenchymal Stromal Cells Anno 2019: Dawn of the Therapeutic Era? Concise Review

Martin J Hoogduijn et al. Stem Cells Transl Med. 2019 Nov.

Abstract

2018 was the year of the first marketing authorization of an allogeneic stem cell therapy by the European Medicines Agency. The authorization concerns the use of allogeneic adipose tissue-derived mesenchymal stromal cells (MSCs) for treatment of complex perianal fistulas in Crohn's disease. This is a breakthrough in the field of MSC therapy. The last few years have, furthermore, seen some breakthroughs in the investigations into the mechanisms of action of MSC therapy. Although the therapeutic effects of MSCs have largely been attributed to their secretion of immunomodulatory and regenerative factors, it has now become clear that some of the effects are mediated through host phagocytic cells that clear administered MSCs and in the process adapt an immunoregulatory and regeneration supporting function. The increased interest in therapeutic use of MSCs and the ongoing elucidation of the mechanisms of action of MSCs are promising indicators that 2019 may be the dawn of the therapeutic era of MSCs and that there will be revived interest in research to more efficient, practical, and sustainable MSC-based therapies. Stem Cells Translational Medicine 2019;8:1126-1134.

PubMed Disclaimer

Conflict of interest statement

E.L. declared employment, patent holder and stock ownership with TiGenix/Takeda. The other author indicated no potential conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Crisan M, Yap S, Casteilla L et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008;3:301–313. - PubMed
    1. Traktuev DO, Merfeld‐Clauss S, Li J et al. A population of multipotent CD34‐positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ Res 2008;102:77–85. - PubMed
    1. Feng J, Mantesso A, De Bari C et al. Dual origin of mesenchymal stem cells contributing to organ growth and repair. Proc Natl Acad Sci USA 2011;108:6503–6508. - PMC - PubMed
    1. Rasini V, Dominici M, Kluba T et al. Mesenchymal stromal/stem cells markers in the human bone marrow. Cytotherapy 2013;15:292–306. - PubMed
    1. Churchman SM, Ponchel F, Boxall SA et al. Transcriptional profile of native CD271+ multipotential stromal cells: Evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling activity. Arthritis Rheum 2012;64:2632–2643. - PubMed

MeSH terms